Showing results (21-30 of 156) with videos related to

Sort By:
Pageof 16
Molecular Pharmaceutics|October 13, 2011
Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imigluceraseOlga Abian, Pilar Alfonso, Adrian Velazquez-Campoy, et al.
Clinical Chemistry|December 23, 2006
Transcriptional profiling of hematologic malignancies with a low-density DNA microarrayPatricia Alvarez, Pilar Sáenz, David Arteta, et al.
Hematology (Amsterdam, Netherlands)|December 16, 2014
Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective studyAlbert Oriol, Pilar Giraldo, Ioannis Kotsianidis, et al.
Plos One|May 16, 2015
The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher diseaseJavier Gervas-Arruga, Jorge Javier Cebolla, Ignacio de Blas, et al.
Blood Cells, Molecules & Diseases|July 21, 2020
Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?Marcio Andrade-Campos, Beatriz Escuder-Azuara, Laura López de Frutos, et al.
Epilepsia|April 17, 2007
Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combinationJose L Capablo, Rafael Franco, Alicia Sáenz de Cabezón, et al.
Blood Cells, Molecules & Diseases|July 26, 2005
Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutationsPilar Alfonso, Sandra Pampín, Jorge Estrada, et al.
Haematologica|March 15, 2006
Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 casesJuan-Manuel Sancho, Josep-Maria Ribera, Maria-José Romero, et al.
Clinical Case Reports|May 11, 2018
Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneouslyMSoledad Noya, Marcio Andrade-Campos, Pilar Irun, et al.
Medicina Clinica|May 16, 2003
[Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease]Pilar Alfonso, Ana Cenarro, Juan Ignacio Pérez-Calvo, et al.
Pageof 16